Atlas FDA

NUXFLEXXA (SODIUM HYALURONATE)

FDA premarket approval P010029/S001 · decided 2006-02-27

Approval details

PMA number
P010029
Supplement
S001
Supplement type
Normal 180 Day Track
Trade name
NUXFLEXXA (SODIUM HYALURONATE)
Generic name
Acid, hyaluronic, intraarticular
Applicant
Ferring Pharmaceuticals, Inc.
Date received
2005-01-13
Decision date
2006-02-27
Days to decision
410 days
Decision code
APPR
Product code
MOZ
Advisory committee
Orthopedic
Expedited review
No
Location
Parsippany, NJ
Statement
APPROVAL FOR 1) CHANGING THE STORAGE CONDITIONS SPECIFIED IN THE PRODUCT LABELING FROM, ?STORE IN A COLD DARK PLACE [2 ? 8 DEGREES C (36-46 DEGREES F)]. PROTECT FROM LIGHT. DO NOT FREEZE?. 2) CHANGE THE SPECIFIED SHELF LIFE TIME IN THE LABELING FORM 3 YEARS (AT REFRIGERATED TEMPERATURES) TO 12 MONTHS. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME EUFLEXXA AND IS INDICATED FOR THE TREATMENT OF PAIN IN OSTEOARTHRITIS (OA) OF THE KNEE IN PATIENTS WHO HAVE FAILED TO RESPOND ADEQUATE

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.